Eckert & Ziegler (EUZ) Q3 2024 earnings summary

Executive summary

• Revenue for the first nine months of 2024 rose 17% year-over-year to €216 million, driven by strong growth in Medical and Isotope Products segments, with Medical up 26% and Isotope Products up 10%.

• Medical segment exceeded €100 million in sales for the first time, with 31% adjusted EBIT growth; Isotope Products also surpassed €100 million.

• Operational cash flow surged 158% to €45.1 million, supporting investments and liquidity.

• Major operational highlights include European approval for GalliaPharm®, a CMO agreement with Telix, and the opening of a new facility in Dresden.

• The Pentixapharm spin-off became legally effective in October, separating it from the combined results.

Financial highlights

• Adjusted EBIT rose 24% year-over-year to €46.7 million, with margin reaching 22%; Medical segment EBIT margin at 23% and Isotope Products at 22%.

• Gross profit and margin increased despite higher depreciation and personnel costs from new projects.

• Cash and cash equivalents rose to €97.6 million as of September 30, 2024; equity ratio improved to 52%.

• Headcount increased 7–8% to 1,143 by September.

• Investments decreased sharply to €1.4 million, and loan liabilities fell 18% to €21.5 million.

Outlook and guidance

• 2024 guidance reaffirmed: expected revenue of €265 million and adjusted EBIT of €55 million, with order book full for early next year.

• Product mix in Isotope Products expected to weaken in Q4, with full-year gross margin anticipated at 2023 levels.

• Continued strong demand for generators, especially in North America, with new markets like Japan and China anticipated to contribute in coming years.

• Commercial production and isotope supply for pharma partners expected to drive mid- to long-term growth.

• No risks identified that threaten the company’s continued existence.